Loading stock data…
$23.77-1.24 (-4.94%)
Biodesix, Inc.
Biodesix, Inc. in the Healthcare sector is trading at $23.77 with a market capitalization of $282M. Wall Street consensus targets $39.00 (6 analysts), implying a +64.1% move over the next 12 months. The stock is currently 26% below its 52-week high of $31.97, remaining 34.3% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $26.86M↑ | $25.55M↓ | $28.75M↑ | $21.77M↑ | $20.02M |
| Gross Profit | $22.04M↑ | $21.35M↓ | $23.88M↑ | $17.66M↑ | $15.99M |
| Operating Income | -$5.38M↑ | -$6.20M↓ | -$1.97M↑ | -$7.04M↑ | -$9.69M |
| Net Income | -$7.27M↑ | -$7.79M↓ | -$3.98M↑ | -$8.72M↑ | -$11.47M |
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identi...